Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Olema Oncology (Nasdaq: OLMA) granted inducement stock options to five new employees to purchase an aggregate of 148,600 shares, effective November 3, 2025. The awards were approved by the Compensation Committee under the 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The options vest over four years (25% after one year, then monthly for 36 months), have a 10-year term, and an exercise price of $8.42 per share, equal to the last reported sale price on Nasdaq on November 3, 2025.

SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to five new employees to purchase an aggregate of 148,600 shares of the Company's common stock, effective as of November 3, 2025. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of $8.42 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on November 3, 2025. The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan.

Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.

Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com

FAQ

What did Olema (OLMA) announce on November 4, 2025 regarding stock grants?

Olema announced inducement stock options for five new employees to buy a total of 148,600 shares, effective Nov 3, 2025.

What is the vesting schedule for the OLMA inducement options granted Nov 3, 2025?

Options vest over 4 years: 25% after the first year, then the remainder in 36 equal monthly installments.

What is the exercise price and term of the OLMA options granted under the 2022 Inducement Plan?

The options carry a $8.42 exercise price and a 10-year term.

Under which Nasdaq rule were Olema's Nov 2025 inducement grants made?

The grants were made under Nasdaq Listing Rule 5635(c)(4) as inducement awards for new employees.

How many employees received inducement options from Olema and how many shares are covered?

Five new employees received options covering an aggregate of 148,600 shares.

Are the OLMA options conditional on continued employment?

Yes, vesting is subject to each employee being continuously employed through the applicable vesting dates.